353 related articles for article (PubMed ID: 10026839)
1. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
[TBL] [Abstract][Full Text] [Related]
2. Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans.
Weber R; Pechère-Bertschi A; Hayoz D; Gerc V; Brouard R; Lahmy JP; Brunner HR; Burnier M
Hypertension; 1997 Nov; 30(5):1121-7. PubMed ID: 9369265
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women.
Steinwall M; Bossmar T; Gaud C; Akerlund M
Acta Obstet Gynecol Scand; 2004 Jan; 83(1):12-8. PubMed ID: 14678081
[TBL] [Abstract][Full Text] [Related]
4. Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3T3 cells.
Serradeil-Le Gal C; Bourrié B; Raufaste D; Carayon P; Garcia C; Maffrand JP; Le Fur G; Casellas P
Biochem Pharmacol; 1994 Feb; 47(4):633-41. PubMed ID: 8129742
[TBL] [Abstract][Full Text] [Related]
5. V1a- and V2-type vasopressin receptors mediate vasopressin-induced Ca2+ responses in isolated rat supraoptic neurones.
Gouzénes L; Sabatier N; Richard P; Moos FC; Dayanithi G
J Physiol; 1999 Jun; 517 ( Pt 3)(Pt 3):771-9. PubMed ID: 10358117
[TBL] [Abstract][Full Text] [Related]
6. Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.
Serradeil-Le Gal C; Herbert JM; Delisee C; Schaeffer P; Raufaste D; Garcia C; Dol F; Marty E; Maffrand JP; Le Fur G
Am J Physiol; 1995 Jan; 268(1 Pt 2):H404-10. PubMed ID: 7840290
[TBL] [Abstract][Full Text] [Related]
7. Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients.
Thibonnier M; Kilani A; Rahman M; DiBlasi TP; Warner K; Smith MC; Leenhardt AF; Brouard R
Hypertension; 1999 Dec; 34(6):1293-300. PubMed ID: 10601133
[TBL] [Abstract][Full Text] [Related]
8. Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin-induced uterine contractions.
Bossmar T; Brouard R; Döberl A; Akerlund M
Br J Obstet Gynaecol; 1997 Apr; 104(4):471-7. PubMed ID: 9141585
[TBL] [Abstract][Full Text] [Related]
9. Effects of SR 49059, a non-peptide antagonist of vasopressin V1a receptors, on vasopressin-induced coronary vasoconstriction in conscious rabbits.
Serradeil-Le Gal C; Villanova G; Boutin M; Maffrand JP; Le Fur G
Fundam Clin Pharmacol; 1995; 9(1):17-24. PubMed ID: 7768483
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.
Serradeil-Le Gal C; Wagnon J; Garcia C; Lacour C; Guiraudou P; Christophe B; Villanova G; Nisato D; Maffrand JP; Le Fur G
J Clin Invest; 1993 Jul; 92(1):224-31. PubMed ID: 8392086
[TBL] [Abstract][Full Text] [Related]
11. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
[TBL] [Abstract][Full Text] [Related]
12. Lack of effect of a selective vasopressin V1A receptor antagonist SR 49,059, on potentiation by vasopressin of adrenoceptor-mediated pressor responses in the rat mesenteric arterial bed.
Heinemann A; Horina G; Stauber RE; Pertl C; Holzer P; Peskar BA
Br J Pharmacol; 1998 Nov; 125(6):1120-7. PubMed ID: 9863637
[TBL] [Abstract][Full Text] [Related]
13. Effects of the vasopressin V1a receptor antagonist, SR 49059, on the response of human uterine arteries to vasopressin and other vasoactive substances.
Kostrzewska A; Laudanski T; Steinwall M; Bossmar T; Serradeil-Le Gal C; Akerlund M
Acta Obstet Gynecol Scand; 1998 Jan; 77(1):3-7. PubMed ID: 9492709
[TBL] [Abstract][Full Text] [Related]
14. Vasopressin(4-9) fragment activates V1a-type vasopressin receptor in rat supraoptic neurones.
Gouzènes L; Dayanithi G; Moos FC
Neuroreport; 1999 Jun; 10(8):1735-9. PubMed ID: 10501566
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibitory effect of SR 49059, an orally active non-peptide vasopressin VIa receptor antagonist, on human arterial coronary bypass graft.
Liu JJ; Chen JR; Buxton BB; Johnston CI; Burrell LM
Clin Sci (Lond); 1995 Nov; 89(5):481-5. PubMed ID: 8549062
[TBL] [Abstract][Full Text] [Related]
16. Effect of the non-peptide, vasopressin V1a receptor antagonist, SR 49059 and its enantiomer, SR 49770, on isolated human myometrium.
Bossmar T; Rasmussen T; Akerlund M
Acta Obstet Gynecol Scand; 1996 Jul; 75(6):516-9. PubMed ID: 8693925
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the effect of arginine-vasopressin on water and ion transport in the newt early distal tubule and frog urinary bladder by V1-antagonists.
Goncharevskaya OA; Shakhmatova EI; Natochin YV
Pflugers Arch; 1995 Oct; 430(6):1004-11. PubMed ID: 8594534
[TBL] [Abstract][Full Text] [Related]
18. Binding of the non-peptide vasopressin V1a receptor antagonist SR-49059 in the rat brain: an in vitro and in vivo autoradiographic study.
Tribollet E; Raufaste D; Maffrand J; Serradeil-Le Gal C
Neuroendocrinology; 1999 Feb; 69(2):113-20. PubMed ID: 9986924
[TBL] [Abstract][Full Text] [Related]
19. Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist.
Serradeil-Le Gal C
Adv Exp Med Biol; 1998; 449():427-38. PubMed ID: 10026834
[TBL] [Abstract][Full Text] [Related]
20. Oxytocin and vasopressin constrict rat isolated uterine resistance arteries by activating vasopressin V1A receptors.
Chen YL; Shepherd C; Spinelli W; Lai FM
Eur J Pharmacol; 1999 Jul; 376(1-2):45-51. PubMed ID: 10440088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
